Syndax Pharmaceuticals (SNDX) News Today $15.83 -0.96 (-5.72%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Syndax confirms FDA approval of Revuforj for acute leukemiaNovember 16 at 9:07 AM | markets.businessinsider.comFDA approves Syndax’s Revuforj for acute leukemiaNovember 16 at 2:50 AM | markets.businessinsider.comSyndax Pharmaceuticals (NASDAQ:SNDX) Raised to Hold at StockNews.comStockNews.com upgraded shares of Syndax Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Friday.November 16 at 12:11 AM | marketbeat.comUS FDA approves Syndax's blood cancer drugNovember 15 at 6:26 PM | reuters.comSyndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A TranslocationNovember 15 at 5:29 PM | prnewswire.comSimplify Asset Management Inc. Acquires 46,992 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)Simplify Asset Management Inc. raised its holdings in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 62.5% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 122,185 shares of the company's stock after acquiring an additional 46,992 shareNovember 15 at 11:16 AM | marketbeat.comSyndax Pharmaceuticals: Promising Phase 2 Results Justify Buy Rating Amid Market UndervaluationNovember 14 at 10:54 AM | markets.businessinsider.comSyndax price target lowered to $18 from $23 at ScotiabankNovember 14 at 1:32 AM | markets.businessinsider.comSyndax's Revumenib Trial Reports Positive Data In Relapsed/Refractory MNPM1 AML PatientsNovember 12, 2024 | markets.businessinsider.comSyndax falls after mid-stage data for leukemia drugNovember 12, 2024 | msn.comSyndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of RevumenibNovember 12, 2024 | prnewswire.comSyndax Pharmaceuticals (NASDAQ:SNDX) Upgraded by StockNews.com to "Hold" RatingNovember 11, 2024 | americanbankingnews.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives $35.82 Average Target Price from BrokeragesNovember 11, 2024 | americanbankingnews.comAnalysts Are Updating Their Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Estimates After Its Third-Quarter ResultsNovember 9, 2024 | finance.yahoo.comWhat is HC Wainwright's Forecast for SNDX FY2024 Earnings?Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) - HC Wainwright boosted their FY2024 EPS estimates for shares of Syndax Pharmaceuticals in a research report issued on Wednesday, November 6th. HC Wainwright analyst E. White now forecasts that the company will post earnings per share of ($November 8, 2024 | marketbeat.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Rating of "Moderate Buy" from AnalystsSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eleven ratings firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and ten have assigned a buyNovember 8, 2024 | marketbeat.comScotiabank Remains a Hold on Syndax Pharmaceuticals (SNDX)November 7, 2024 | markets.businessinsider.comQ3 2024 Syndax Pharmaceuticals Inc Earnings CallNovember 7, 2024 | finance.yahoo.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q3 2024 Earnings Call TranscriptNovember 7, 2024 | msn.comSyndax Pharmaceuticals: Buy Rating Backed by Promising Revumenib Developments and Growth CatalystsNovember 7, 2024 | markets.businessinsider.comSyndax Pharmaceuticals (SNDX) Receives a Buy from Stifel NicolausNovember 7, 2024 | markets.businessinsider.comSyndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $33.00The Goldman Sachs Group upped their target price on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the company a "buy" rating in a research report on Thursday.November 7, 2024 | marketbeat.comSyndax Pharmaceuticals Inc (SNDX) Q3 2024 Earnings Call Highlights: Strategic Advances and ...November 6, 2024 | uk.finance.yahoo.comSyndax Pharmaceuticals: Key Pipeline Developments and Financial UpdateNovember 6, 2024 | markets.businessinsider.comSyndax Pharmaceuticals (NASDAQ:SNDX) Given New $47.00 Price Target at HC WainwrightHC Wainwright boosted their price objective on Syndax Pharmaceuticals from $45.00 to $47.00 and gave the company a "buy" rating in a research report on Wednesday.November 6, 2024 | marketbeat.comSyndax Pharmaceuticals, Inc. (SNDX) Q3 2024 Earnings Call TranscriptNovember 5, 2024 | seekingalpha.comSyndax Pharmaceuticals, Inc. 2024 Q3 - Results - Earnings Call PresentationNovember 5, 2024 | seekingalpha.comSyndax Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 5, 2024 | prnewswire.comSyndax to Host ASH Investor Event in Person and via Webcast on December 9, 2024November 5, 2024 | prnewswire.comSyndax Announces New Data from Secondary Analysis of the Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease to Be Presented at 66th ASH Annual MeetingNovember 5, 2024 | prnewswire.comSyndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual MeetingNovember 5, 2024 | prnewswire.comRoyalty Pharma enters $350M synthetic royalty funding agreement with SyndaxNovember 5, 2024 | markets.businessinsider.comSyndax, Royalty Pharma enter $350M royalty funding agreement for NiktimvoNovember 5, 2024 | markets.businessinsider.comSyndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™November 4, 2024 | prnewswire.comSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)November 1, 2024 | prnewswire.comSyndax Announces Participation in November Investor ConferencesNovember 1, 2024 | prnewswire.comSyndax Pharmaceuticals (SNDX) Scheduled to Post Earnings on TuesdaySyndax Pharmaceuticals (NASDAQ:SNDX) will be releasing earnings after the market closes on Tuesday, November 5, Zacks reports.October 30, 2024 | marketbeat.comSyndax to Announce Third Quarter 2024 Financial Results and Host Conference Call and Webcast on November 5, 2024October 29, 2024 | prnewswire.comAssenagon Asset Management S.A. Buys 37,079 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)Assenagon Asset Management S.A. increased its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 8.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 466,028 sOctober 29, 2024 | marketbeat.comUBS Initiates Coverage of Syndax Pharmaceuticals (SNDX) with Buy RecommendationOctober 26, 2024 | msn.comSyndax initiated with a Buy at UBSOctober 24, 2024 | markets.businessinsider.comSyndax Pharmaceuticals (NASDAQ:SNDX) Coverage Initiated by Analysts at UBS GroupUBS Group started coverage on shares of Syndax Pharmaceuticals in a research report on Thursday. They issued a "buy" rating and a $37.00 target price on the stock.October 24, 2024 | marketbeat.comState Street Corp's Strategic Acquisition in Syndax PharmaceuticalsOctober 18, 2024 | finance.yahoo.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by AQR Capital Management LLCAQR Capital Management LLC lowered its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 48.8% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 27,273 shares of the companOctober 15, 2024 | marketbeat.comKura downgraded to hold by Stifel, prefers rival SyndaxOctober 14, 2024 | msn.comSyndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $41.00Stifel Nicolaus lifted their target price on Syndax Pharmaceuticals from $40.00 to $41.00 and gave the stock a "buy" rating in a research note on Monday.October 14, 2024 | marketbeat.comDimensional Fund Advisors LP Has $1.44 Million Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)Dimensional Fund Advisors LP trimmed its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 35.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 70,181 shares of the company's stock after sellOctober 13, 2024 | marketbeat.comSyndax Pharmaceuticals Inc (SNDX) Q2 2024 Earnings Call Highlights: Strategic Advances and ...October 9, 2024 | finance.yahoo.comHealthcare of Ontario Pension Plan Trust Fund Decreases Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)Healthcare of Ontario Pension Plan Trust Fund trimmed its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 70.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 228,625 shares of theOctober 6, 2024 | marketbeat.comMillennium Management LLC Grows Stock Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)Millennium Management LLC lifted its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 56.3% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,065,508 shares of the company's stock after acquiring an adOctober 5, 2024 | marketbeat.com Get Syndax Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter. Email Address Let’s be blunt (Ad)Let me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)! Check out the $100 Challenge now SNDX Media Mentions By Week SNDX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SNDX News Sentiment▼0.660.55▲Average Medical News Sentiment SNDX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SNDX Articles This Week▼165▲SNDX Articles Average Week Get Syndax Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AMPH News ENTA News ELAN News BPMC News CYTK News NUVL News KRYS News RNA News BHVN News RARE News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SNDX) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syndax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Syndax Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SNDX Stock Alerts